Approximately 15%-20% of breast cancers exhibit HER2 amplification or overexpression (3), and the development of anti-HER2 therapies has significantly improved treatment outcomes for HER2-positive breast cancer (2, 4–6). Here, ERBB2 is linked to breast carcinoma.